Journal article · 2017 · Open access

Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome

Thomas A. Rasmussen, James H. McMahon, J. Judy Chang, Jori Symons, Michael Roche, Ashanti Dantanarayana, Afam A. Okoye, Bonnie M. Hiener, Sarah Palmer, Wen Shi Lee, Stephen John Kent, Carrie van der Weyden and 3 more

AIDS, 31(13), 1839–1845 · Published 16 May 2017 · DOI 10.1097/qad.0000000000001540

Open full textView at the publisherCite this paper

In brief

“Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome” is a 2017 journal article by Thomas A. Rasmussen and 14 co-authors, published in AIDS. OpenAlex counts 13 citations as of 19 November 2026. It is open access: the full text is free to read at Europe PMC (PubMed Central).

Citations
13
Most cited in
2018 (2)
Field-weighted impact
0.78
References
27
Authors
15

Abstract

OBJECTIVE: To study the effects of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy (ART) with Sezary syndrome, a rare malignancy of CD4 T cells. DESIGN: Case report. METHODS: Blood was collected 30 and 18 months prior to presentation with Sezary syndrome, at the time of presentation and during alemtuzumab. T-cell subsets in malignant (CD7-CD26-TCR-VBeta2+) and nonmalignant cells were quantified by flow cytometry. HIV-DNA in total CD4 T cells, in sorted malignant and nonmalignant CD4 T cells, was quantified by PCR and clonal expansion of HIV-DNA assessed by full-length next-generation sequencing. RESULTS: HIV-hepatitis B virus coinfection was diagnosed and antiretroviral therapy initiated 4 years prior to presentation with Sezary syndrome and primary cutaneous anaplastic large cell lymphoma. The patient received alemtuzumab 10 mg three times per week for 4 weeks but died 6 weeks post alemtuzumab. HIV-DNA was detected in nonmalignant but not in malignant CD4 T cells, consistent with expansion of a noninfected CD4 T-cell clone. Full-length HIV-DNA sequencing demonstrated multiple defective viruses but no identical or expanded sequences. Alemtuzumab extensively depleted T cells, including more than 1 log reduction in total T cells and more than 3 log reduction in CD4 T cells. Finally, alemtuzumab decreased HIV-DNA in CD4 T cells by 57% but HIV-DNA remained detectable at low levels even after depletion of nearly all CD4 T cells. CONCLUSION: Alemtuzumab extensively depleted multiple T-cell subsets and decreased the frequency of but did not eliminate HIV-infected CD4 T cells. Studying the effects on HIV persistence following immune recovery in HIV-infected individuals who require alemtuzumab for malignancy or in animal studies may provide further insights into novel cure strategies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rasmussen, T. A., McMahon, J. H., Chang, J. J., Symons, J., Roche, M., Dantanarayana, A., Okoye, A. A., Hiener, B. M., Palmer, S., Lee, W. S., Kent, S. J., van der Weyden, C., Prince, H. M., Cameron, P. U., & Lewin, S. R. (2017). Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. AIDS, 31(13), 1839–1845. https://doi.org/10.1097/qad.0000000000001540

MLA 9

Rasmussen, Thomas A., et al. “Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.” AIDS, vol. 31, no. 13, 2017, pp. 1839–1845. https://doi.org/10.1097/qad.0000000000001540.

Chicago

Rasmussen, Thomas A., James H. McMahon, J. Judy Chang, Jori Symons, Michael Roche, Ashanti Dantanarayana, Afam A. Okoye, et al. 2017. “Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.” AIDS 31 (13): 1839–1845. https://doi.org/10.1097/qad.0000000000001540.

Harvard

Rasmussen, T. A. et al. (2017) ‘Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome’, AIDS, 31(13), pp. 1839–1845. doi:10.1097/qad.0000000000001540.

IEEE

T. A. Rasmussen et al., “Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome,” AIDS, vol. 31, no. 13, pp. 1839–1845, 2017, doi: 10.1097/qad.0000000000001540.

BibTeX

@article{rasmussen2017impact,
  title     = {{Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome}},
  author    = {Rasmussen, Thomas A. and McMahon, James H. and Chang, J. Judy and Symons, Jori and Roche, Michael and Dantanarayana, Ashanti and Okoye, Afam A. and Hiener, Bonnie M. and Palmer, Sarah and Lee, Wen Shi and Kent, Stephen John and van der Weyden, Carrie and Prince, Henry Miles and Cameron, Paul U. and Lewin, Sharon R.},
  journal   = {AIDS},
  year      = {2017},
  volume    = {31},
  number    = {13},
  pages     = {1839--1845},
  doi       = {10.1097/qad.0000000000001540},
  url       = {https://doi.org/10.1097/qad.0000000000001540}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201711
201822
201911
202022
202211
202322
202422
202511
202611

Its field-weighted citation impact is 0.78: it has been cited 0.78 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment

  • alemtuzumab
  • HIV persistence
  • Sézary syndrome
  • CD4+ T cell depletion
  • HIV DNA
  • primary cutaneous anaplastic large cell lymphoma
  • HIV cure strategies
  • immune reconstitution

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Rasmussen, T. A., McMahon, J. H., Chang, J. J., Symons, J., Roche, M., Dantanarayana, A., Okoye, A. A., Hiener, B. M., Palmer, S., Lee, W. S., Kent, S. J., van der Weyden, C., Prince, H. M., Cameron, P. U., & Lewin, S. R. (2017). Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. AIDS, 31(13), 1839–1845. https://doi.org/10.1097/qad.0000000000001540

How many times has this paper been cited?

13 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.

Who wrote this paper?

Thomas A. Rasmussen, James H. McMahon, J. Judy Chang, Jori Symons, Michael Roche, Ashanti Dantanarayana, Afam A. Okoye, Bonnie M. Hiener, Sarah Palmer, Wen Shi Lee, Stephen John Kent, Carrie van der Weyden and 3 more.

What is the DOI of this paper?

10.1097/qad.0000000000001540, permanently at https://doi.org/10.1097/qad.0000000000001540. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.